Wyeth

Genetics Institute, Inc.

Elixir Pharmaceuticals, Inc.

Thomas E McDonagh

Edward R LaVallie

Christopher John Corcoran

Katy Evangelia Georgiadis

Guang-Yi Xu

Ravindra Kumar

Jasbir S Seehra

Phaik-Eng Sum

Lisa A Racie

Lih-Ling Lin

Mark L Stahl

Russell Thomas

Lidia Mosyak

Lisa Anne Collins-Racie

William Stuart Somers

Bethany Annis Freeman

Carl Ralph Flannery

Xiaotian Zhong

Stephane Olland

Thomas Saltmarsh Rush, Iii

Jean-Francois Pons

Jean-Baptiste Telliez

Jonathan M Solomon

Andrew Napper

Peter DiStefano

Rory A Curtis

L Julie Huber

Stewart Andrews Mackie

Tracy Hebert

Desiree H H Tsao

Sang Hsu

Jeffrey Hixon

A Karl Malakian

Weilan Zeng

Hsiang-Ai Yu

Jin Hong

Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.

SirT inhibitors that bind to NAD

This invention relates to aggrecanase polypeptides and aggrecanase polypeptide/ligand complexes, crystals of aggrecanase and aggrecanase polypeptide/ligand complexes, and related methods and software systems.

Aggrecanase structure

The present invention relates to the three dimensional solution structure of the N-terminal domain of TNFR-1 associated death domain protein ('N-TRADD'), as well as the identification and characterization of a C-TRAF2 binding active site of N-TRADD. Also provided for by the present invention are methods of utilizing the three dimensional structures for the design and selection of potent and selective inhibitors of TNF signaling pathways.

N-TRADD active site and uses thereof

The present invention relates to modified ADAMTS4 proteins having improved stability comparing to the corresponding native, unmodified proteins. The modified ADAMTS4 proteins can be expressed and isolated in large quantities, thus allowing further characterization of the proteins, such as crystallographic and enzyme kinetic studies. The purified, stable proteins would also facilitate the production of anti-ADAMTS antibodies and the development of inhibitors to ADAMTS enzymes.

Modified ADAMTS4 molecules and method of use thereof

Crystallographic and NMR solution structures of human IL-6 are reported. The invention provides models and systems incorporating such structures which are useful for identifying IL-6/IL-6 receptor interactions and for identification of agonists and antagonists of such interactions. Crystalline human IL-6 is also provided.

Crystalline IL-6 and models of the molecular structure of IL-6

Growing community of inventors

Wayland, MA, United States of America

Thomas E McDonagh